Comparison of efficacy and safety of topiramate with gabapentin in migraine prophylaxis: randomized open label control trial

in severity from 6.60±2.122 to 1.03±0.92 in the topiramate group was also significantly greater compared with 6.93±1.90 to 1.18±1.01 in the gabapentin group (p<0.001). Reduction in the average duration of attacks from 25.77±22.32 hours to 1.05±1.06 hours in the topiramate group was significantly greater compared with 22.20±20.72 to 1.08±1.40 hours in the gabapentin group (p<0.001). Weight loss and numbness were common adverse effects in the topiramate group. Dizziness, weight gain and somnolence were reported in the gabapentin group. Conclusion: Gabapentin appeared well tolerated in 30(75%) patients compared to topiramate in 23(57.5%) patients. Both drugs were equally effective in migraine prophylaxis.